Drug · PARP inhibitor · PARP inhibitor · Verified drug
Olaparib (Lynparza) structure · mechanism
PARP1/2 inhibitor — synthetic lethality in BRCA-mutant tumors.
Olaparib (Lynparza) 2D structure
- Role
- Drug
- Mechanism class
- PARP inhibitor
- Aliases
- lynparza
- Parent scaffold
- PARP nicotinamide pharmacophore
- Indication
- BRCA/HRD tumors (ovarian, breast, prostate, pancreas) · FDA/EMA
- Structure source
- Catalog seed (external identifier on file)
- PubChem CID
- 23725625
- ChEMBL ID
- CHEMBL521686
- FDA / EMA
- FDA/EMA
- ClinicalTrials.gov
- olaparib BRCA
- Regulatory status
- Approved · FDA/EMA · ClinicalTrials.gov · ClinicalTrials.gov
Hand-written analysis
Mechanism
올라파립은 PARP1/2 촉매 저해와 DNA 트랩핑으로 BRCA1/2 결손 종양에서 합성치사를 일으킵니다. 촉매 IC50보다 트랩핑 강도가 세포독성을 더 잘 설명합니다. HR 회복 변이가 내성 경로입니다.
Medicinal chemistry
프탈라지논 니코틴아마이드 모사 코어입니다. 탈라조파립보다 트랩핑이 약하고, 니라파립과는 조직 분포·골수 억제가 다릅니다.
Indication · context
난소·유방·전립선·췌장 등 HRR 결손 적응이 있습니다. 같은 패밀리 니라파립·루카파립·탈라조파립과 trapping·BBB를 비교합니다.
SMILES
CC1=CC(=CC(=C1)C2=CC(=CC=C2)C(=O)N3CCCC3)C(=O)NTags
Related compounds
Comparisons · briefs
External IDs · BioMoa
StructureMoa is a chemical-structure exploration tool. Structural similarity, clustering, and SAR relationships are intended for research exploration and do not establish shared potency, selectivity, safety, efficacy, or clinical performance.